Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Naval Daver, Kyoo Hyung Lee, Yunsuk Choi, Brian A. Jonas, Martha Arellano, Paul B. Koller, Chul W. Jung, Sang Kyun Sohn, Amir T. Fathi, Jeong-Ok Lee, Sung-Soo Yoon, Justin M. Watts, Pankit Vachhani, Ho-Jin Shin, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar

Blood (2023) 142 (Supplement 1): 162.

https://doi.org/10.1182/blood-2023-182296

Published: 2023

Journal Articles

The Optimal Busulfan Dose of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Younger Patients with Acute Myeloid Leukemia

Yunsuk Choi, Eun-Ji Choi, Han-Seung Park, Jung-Hee Lee, Kyoo-Hyung Lee, Young-Shin Lee, Young-A Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je-Hwan Lee

Blood (2023) 142 (Supplement 1): 6991.

https://doi.org/10.1182/blood-2023-189327

Published: 2023

Journal Articles

Predicting Disease Progression from Idiopathic Cytopenia of Undetermined Significance to Myeloid Malignancies Using a Machine Learning-Based Approach

Eun-Ji Choi, Jiye Han, Tae Joon Jun, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo Hyung Lee, Young-Hak Kim, Je-Hwan Lee

Blood (2023) 142 (Supplement 1): 7154.

https://doi.org/10.1182/blood-2023-188822

Published: 2023

Journal Articles

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Naval Daver, Kyoo Hyung Lee, Brian A. Jonas, Martha L. Arellano, Chul W. Jung, Sang Kyun Sohn, Sung-Soo Yoon, Jeong-Ok Lee, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6197–6199.

https://doi.org/10.1182/blood-2022-167972

Published: 2022

Journal Articles

Antileukemic Activity of Ypn-005, a CDK7 Inhibitor, Inducing Apoptosis through c-MYC and FLT3 Suppression in Acute Myeloid Leukemia

Bon-Kwan Koo, Je-Hwan Lee, Eun-Ji Choi, Eun-Hye Hur, Ju Hyun Moon, Ji Yun Kim, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo Hyung Lee, Jinhwan Kim

Blood (2022) 140 (Supplement 1): 8803–8804.

https://doi.org/10.1182/blood-2022-168726

Published: 2022

Journal Articles

First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML)

Naval Daver, Kyoo Hyung Lee, Chul Won Jung, Sung-Soo Yoon, Martha L. Arellano, Jiyeon Yoon, Nora Lee, Hyunjin Kim, Jaeyeon Lee, Brian A. Jonas, Seungjae Baek

Blood (2021) 138 (Supplement 1): 702.

https://doi.org/10.1182/blood-2021-150014

Published: 2021

Journal Articles

Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Higher-Risk Myelodysplastic Syndrome

Eun-Ji Choi, Han-Seung Park, Jung-Hee Lee, Kyoo Hyung Lee, Youngshin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je-Hwan Lee

Blood (2021) 138 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2021-150389

Published: 2021

Journal Articles

Similar Survival and Genetic Features between Clonal Cytopenia of Undetermined Significance and Lower-Risk Myelodysplastic Syndrome

Eun-Ji Choi, Young-Uk Cho, Han-Seung Park, Jung-Hee Lee, Kyoo Hyung Lee, Sang-Hyun Hwang, Seongsoo Jang, Chan-jeoung Park, Je-Hwan Lee

Blood (2021) 138 (Supplement 1): 3683.

https://doi.org/10.1182/blood-2021-150368

Published: 2021

Journal Articles

Machine Learning-Based Approach to Predict Survival after Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies

Eun-Ji Choi, MDPhD, Je-Hwan Lee, MDPhD, Jun-Hong Park, MD, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Youngshin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Kyoo Hyung Lee, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142337

Published: 2020

Journal Articles

HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study

Naval Daver, MD, Kyoo Hyung Lee, MD PhD, Chul Won Jung, MD PhD, Yoon Sung Soo, MD PhD, Martha L. Arellano, MD, Brian A Jonas, MD PhD, Jiyeon Yoon, PhD, Sooa Jung, PhD, Young Su Noh, PhD, Inhwan Bae, PhD, Song Kim, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143244

Published: 2020

Journal Articles

DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia

Eun-Ji Choi, MD, Young-Uk Cho, MD, Seongsoo Jang, Chan-jeoung Park, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Kyoo Hyung Lee, MD PhD, Eun-Hye Hur, PhD, Nayoung Kim, PhD, Hee Jeong Ouk, MD, Je-Hwan Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3002.

https://doi.org/10.1182/blood-2019-129906

Published: 2019

Journal Articles

Mutational Characteristics and Changing Pattern from Idiopathic Cytopenia of Undetermined Significance to High-Risk Myelodysplastic Syndrome Stratified By IPSS-R

Eun-Ji Choi, MD, Young-Uk Cho, MD, Seongsoo Jang, Chan-jeoung Park, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Kyoo-Hyung Lee, MD PhD, Eun-Hye Hur, PhD, Nayoung Kim, PhD, Hee Jeong Ouk, MD, Je-Hwan Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3009.

https://doi.org/10.1182/blood-2019-125236

Published: 2019

Journal Articles

Clinical Implications of Copy Number Variant Detection from Panel-Based Next-Generation Sequencing Data in Myelodysplastic Syndrome

Je-Hwan Lee, MD PhD, Yoo-Jin Kim, MD PhD, Seung-Hyun Jung, Eun-Hye Hur, Eun-Ji Choi, MD, Kyoo Hyung Lee, MD PhD, Seon-Hee Yim, Hye-Jung Kim, Yong-Rim Kwon, Young-Woo Jeon, MD PhD, Sug Hyung Lee, Yeun-Jun Chung

Blood (2019) 134 (Supplement_1): 4264.

https://doi.org/10.1182/blood-2019-131570

Published: 2019

Journal Articles

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

Naval G. Daver, MD, Kyoo Hyung Lee, MD PhD, Sung-Soo Yoon, MD PhD, Chul Won Jung, MD PhD, Hyun Jeong Kang, Sooa Jung, Sujin Seo, Jiyeon Yoon, Hyunjin Kim, Young Su Noh, Yoonha Seo, Hyeyoung Kwon, Oakpil Han, Seungjae Baek, MD PhD, Kyounghee Seo, Kwee Hyun Suh, PhD

Blood (2019) 134 (Supplement_1): 1331.

https://doi.org/10.1182/blood-2019-129670

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

Hawk Kim, MD PhD, Yunsuk Choi, MD, Sung-Soo Yoon, MD PhD, Soo-Mee Bang, MD PhD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Yong Park, MD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Ho Sup Lee, MD, Min Kyoung Kim, MD PhD, Won-Sik Lee, Jeong-Yeal Ahn, MD, Kyoo-Hyung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2018-99-116190

Published: 2018

Journal Articles

Decitabine Versus Intensive Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Eun-Ji Choi, MD, Je-Hwan Lee, MD PhD, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Kyoo Hyung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 2713.

https://doi.org/10.1182/blood-2018-99-116102

Published: 2018

Journal Articles

Pilot Prospective Phase II Study of Nilotinib Combined with Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Acute Myeloid Leukemia with BCR/ABL1

Hawk Kim, MD PhD, Yunsuk Choi, MD, Sung-Soo Yoon, MD PhD, Won-Sik Lee, Jee Hyun Kong, MD, Kyoo-Hyung Lee, MD PhD, Jeong-Yeal Ahn, MD, Sang Kyun Sohn, MD PhD

Blood (2018) 132 (Supplement 1): 3020.

https://doi.org/10.1182/blood-2018-99-116488

Published: 2018

Journal Articles

Androgen Therapy for Lower-Risk Myelodysplastic Syndrome

Eun-Ji Choi, MD, Je-Hwan Lee, MD PhD, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Kyoo Hyung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 1823.

https://doi.org/10.1182/blood-2018-99-115931

Published: 2018

Journal Articles

Intravenous Busulfan-Based Conditioning Regimens in Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia

Sun-Hye Ko, MD PhD, Jung-Hee Lee, MD PhD, Han-Seung Park, MD, Je-Hwan Lee, MD PhD, Eun-ji Choi, MD, Miee Seol, Young-Shin Lee, RN, Young-Ah Kang, Mijin Jeon, Kyoo Hyung Lee, MD PhD

Blood (2017) 130 (Supplement 1): 3214.

https://doi.org/10.1182/blood.V130.Suppl_1.3214.3214

Published: 2017

NARROW

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

The Optimal Busulfan Dose of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Younger Patients with Acute Myeloid Leukemia

Predicting Disease Progression from Idiopathic Cytopenia of Undetermined Significance to Myeloid Malignancies Using a Machine Learning-Based Approach

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Antileukemic Activity of Ypn-005, a CDK7 Inhibitor, Inducing Apoptosis through c-MYC and FLT3 Suppression in Acute Myeloid Leukemia

First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML)

Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Higher-Risk Myelodysplastic Syndrome

Similar Survival and Genetic Features between Clonal Cytopenia of Undetermined Significance and Lower-Risk Myelodysplastic Syndrome

Machine Learning-Based Approach to Predict Survival after Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies

HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study

DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia

Mutational Characteristics and Changing Pattern from Idiopathic Cytopenia of Undetermined Significance to High-Risk Myelodysplastic Syndrome Stratified By IPSS-R

Clinical Implications of Copy Number Variant Detection from Panel-Based Next-Generation Sequencing Data in Myelodysplastic Syndrome

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

Decitabine Versus Intensive Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Pilot Prospective Phase II Study of Nilotinib Combined with Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Acute Myeloid Leukemia with BCR/ABL1

Androgen Therapy for Lower-Risk Myelodysplastic Syndrome

Intravenous Busulfan-Based Conditioning Regimens in Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only